This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Myriad Genetics Gets Extended Coverage for Prolaris Test
by Zacks Equity Research
Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN) recently received extended Medicare coverage for its Prolasis test.
Henry Schein (HSIC) Rides on Global Growth, Strategic Deals
by Zacks Equity Research
On May 25 2017, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Patterson Companies (PDCO) Earnings Beat Estimates in Q4
by Zacks Equity Research
Patterson Companies Inc. (PDCO) reported fourth-quarter fiscal 2017 adjusted earnings of 69 cents per share from continuing operations, which outpaced the Zacks Consensus Estimate of 64 cents.
Veeva Systems (VEEV) Beats Q1 Earnings, Revenues Estimates
by Zacks Equity Research
Veeva Systems Inc. (VEEV) reported first-quarter fiscal 2018, adjusted earnings of 14 cents per share, ending Apr 30, 2017.
Stryker (SYK) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Stryker Corporation (SYK), headquartered in Kalamazoo, MI, scaled a new 52-week high of $141.21 on May 25, eventually closing a little lower at $140.85.
Quest Diagnostics Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of Madison, NJ-based Quest Diagnostics, Inc. (DGX) scaled a new 52-week high of $108.52 on May 16, eventually closing a bit lower at $108.14.
Align Technology Rises with Invisalign, SmartTrack Patents
by Zacks Equity Research
Align Technology (ALGN) has received two U.S. Patents from the United States Patent and Trademark Office (USPTO) for its SmartTrack clear aligner material.
Medtronic (MDT) Tops Q4 Earnings, Sales on Balanced Growth
by Zacks Equity Research
Medtronic plc's (MDT) fourth-quarter fiscal 2017 adjusted earnings per share came in at $1.33, a couple of cents ahead of the Zacks Consensus Estimate.
Medtronic Puts First Patient in IN.PACT AV Access DCB Study
by Zacks Equity Research
Medtronic plc (MDT), announced the first patient enrollment under its IN.PACT AV Access Drug-Coated Balloon (DCB) study for patients with end-stage renal disease (ESRD).
Boston Scientific (BSX) BT Study on Asthma Results Positive
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently unveiled positive outcome from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study.